BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abrantes JA, Solms A, Garmann D, Nielsen EI, Jönsson S, Karlsson MO. Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII. CPT Pharmacometrics Syst Pharmacol 2019;8:894-903. [PMID: 31668021 DOI: 10.1002/psp4.12464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Owaidah TM, Alzahrani HA, Al-Numair NS, Alnosair AO, Aguilos AM, Saleh M. Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients. Adv Hematol 2020;2020:8768074. [PMID: 32963537 DOI: 10.1155/2020/8768074] [Reference Citation Analysis]
2 Zapotocka E, Batorova A, Bilic E, Boban A, Escuriola Ettingshausen C, Faganel Kotnik B, Hrdlickova R, Laguna P, Machal J, Nemes L, Zupan IP, Puras G, Zombori M. First experience of a hemophilia monitoring platform: florio HAEMO. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12685] [Reference Citation Analysis]
3 Centanni M, Friberg LE. Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors. Front Pharmacol 2020;11:316. [PMID: 32226388 DOI: 10.3389/fphar.2020.00316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Abrantes JA, Solms A, Garmann D, Nielsen EI, Jönsson S, Karlsson MO. Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients. Haematologica 2020;105:1443-53. [PMID: 31371418 DOI: 10.3324/haematol.2019.217133] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]